Activating Tregs and Tr1 cells by Antigen-Encapsulating PLG Nanoparticles to Treat Autoimmune Disease: Mechanisms and Clinical Translation

Time: 2:30 pm
day: Day Two | Track B | Afternoon


  • Utilizing antigen-encapsulating PLG nanoparticles (Ag-PLG) to induce tolerance to recapitulate self-tolerance induction in the hematopoietic system
  • Conferring a tolerogenic phenotype via a cGAS/STING-dependent mechanism to induce the induction of CD4+Foxp3, CD4+ Tr1, and CD8+CD122+ regulatory T cells
  • Presenting phase 1/2a clinical trial data showing that Ag-PLG treatment significantly reduces gluten challenge-induced T cell response and gut histopathology in celiac disease patients